| Trial ID: | L2250 |
| Source ID: | NCT00819325
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients
|
| Acronym: |
PPAR-G
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Coronary Artery Disease|Angina Pectoris|Type 2 Diabetes Mellitus|Percutaneous Coronary Intervention
|
| Interventions: |
DRUG: pioglitazone|DRUG: oral hypoglycemic agents
|
| Outcome Measures: |
Primary: The primary IVUS endpoint of the study was the change in three-dimensional neointimal plaque volume within the stented segment at follow-up, compared to baseline., 6 months | Secondary: The secondary IVUS endpoint was the change in the two-dimensional NIA within the stent, using the cross-sectional slice showing the smallest LA on follow-up and comparing it to the corresponding baseline slice., 6 months
|
| Sponsor/Collaborators: |
Sponsor: Queen Elizabeth II Health Sciences Centre | Collaborators: Nova Scotia Health Research Foundation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2002-08
|
| Completion Date: |
2007-03
|
| Results First Posted: |
|
| Last Update Posted: |
2009-01-08
|
| Locations: |
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, B3H 3A7, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00819325
|
